Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative

This page shows the latest neurodegenerative news and features for those working in and with pharma, biotech and healthcare.

FDA expecting boom in cell and gene therapies

FDA expecting boom in cell and gene therapies

and neurodegenerative diseases, and explaining where the accelerated approval pathway may not be applicable – for example if the gene therapy isn’t intended to cure the underlying condition but rather to ... A more traditional approach to drug

Latest news

More from news
Approximately 7 fully matching, plus 105 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Biogen appoints executive VP, corporate development Biogen appoints executive VP, corporate development

    to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”.

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    Francois Nader joins the biotech. Prevail Therapeutics, a biotechnology company focused on the development of gene therapies for patients with neurodegenerative diseases, has strengthened its board of directors with the addition ... The Prevail team has

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Novartis’ Michael Ryan joins the neurodegenerative diseases specialist. Lausanne, Switzerland-based Asceneuron has appointed Michael Ryan as its new chief medical officer. ... He joins the neurodegenerative diseases specialist from Novartis, where he

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    Prof De Strooper is currently a professor of molecular medicine at the University of Leuven and leads its laboratory for the research of neurodegenerative diseases.

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: “Dr Isacson's deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer's and

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Alzheimer's and Brain Awareness Month

    AD is a neurodegenerative disease, meaning that its symptoms are generally mild at the start, but become progressively worse over time, eventually interfering with the everyday life of those affected.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics